Table 1.
Baseline characteristics of patients treated with BT versus EBRT.
| Total | EBRT | BT | P | |
|---|---|---|---|---|
|
| ||||
| Total patients, n | 31,783 | 25,945 | 5,838 | |
| Age, Mean (SD) | 70 (7.5) | 70 (7.4) | 68 (7.7) | < 1 ×10−16 |
| Race | ||||
| White | 25,367 (80) | 20,612 (79) | 4755 (81) | 7.1 × 10−4 |
| Black | 5,563 (17) | 4,607 (18) | 956 (16) | |
| Other | 853 (3) | 726 (3) | 127 (3) | |
| Spanish or Hispanic Origin | ||||
| Non-Spanish, Non-Hispanic | 28,783 (90) | 23,452 (90) | 5,331 (91) | 0.03 |
| Spanish or Hispanic | 3,000 (10) | 2,493 (10) | 507 (9) | |
| Insurance | ||||
| Uninsured | 424 (1) | 363 (1) | 61 (1) | |
| Private Insurance | 8,536 (27) | 6,463 (25) | 2,073 (36) | < 2.2 × 10−16 |
| Medicare | 20,699 (65) | 17,317 (67) | 3,382 (58) | |
| Medicaid/Other Government | 1,666 (5) | 1,403 (5) | 263 (4) | |
| Unknown | 458 (2) | 399 (2) | 59 (1) | |
| Income Level | ||||
| < 38,000 | 6,163 (19) | 5,058 (20) | 1,105 (19) | |
| 38,000–47,999 | 7,562 (24) | 6,095 (23) | 1,467 (25) | 0.005 |
| 48,000–62,999 | 8,462 (27) | 6,875 (27) | 1,587 (27) | |
| > 63,000 | 9,455 (30) | 7808 (30) | 1,647 (28) | |
| Unknown | 141 (0) | 109 (0) | 32 (1) | |
| Education † | ||||
| < 7% | 7,460 (23) | 6,074 (24) | 1,386 (24) | |
| 7–12.9% | 10,680 (34) | 8,748 (34) | 1,932 (33) | 0.004 |
| 13–20.9% | 8,578 (27) | 6,920 (26) | 1,658 (29) | |
| ≥ 21% | 4,947 (16) | 4,112 (16) | 835 (14) | |
| Unknown | 118 (0) | 91 (0) | 27 (0) | |
| CDCI (Comorbidity) Score | ||||
| 0 | 27,511 (87) | 22,569 (87) | 4,942 (85) | 2.6 × 10−6 |
| 1 ‡ | 4,272 (13) | 3,376 (13) | 896 (15) | |
| Treatment at Academic Center | ||||
| No | 22,966 (72) | 18,794 (72) | 4,172 (71) | 0.13 |
| Yes | 8,817 (28) | 7,151 (28) | 1,666 (29) | |
| PSA, Mean (SD) | 8.3 (4.3) | 8.5 (4.3) | 7.5 (4.3) | < 1 ×10−16 |
| Gleason Score | ||||
| 3+3 | 1,503 (5) | 1,156 (4) | 347 (6) | 6.7 × 10−11 |
| 3+4 | 14,043 (44) | 11,334 (44) | 2709 (46) | |
| 4+3 | 16,237 (51) | 13,455 (52) | 2782 (48) | |
| Clinical T Stage | ||||
| ≤ cT2a | 22,736 (72) | 18,280 (71) | 4,456 (76) | < 2.2 × 10−16 |
| T2b-T2c | 8,032 (25) | 6,788 (26) | 1,244 (21) | |
| cT2, NOS | 1,015 (3) | 877 (3) | 138 (3) | |
| ADT | ||||
| No | 17,520 (55) | 12,985 (50) | 4,535 (78) | < 2.2 × 10−16 |
| Yes | 14,263 (45) | 12,960 (50) | 1,303 (22) | |
| Year of Diagnosis | ||||
| 2004–2007 | 8,235 (26) | 6,591 (25) | 1,644 (28) | 3.0 × 10−5 |
| 2008–2010 | 14,249 (45) | 11,671 (45) | 2,578 (44) | |
| 2011–2015 | 9,299 (29) | 7,683 (30) | 1,616 (28) | |
Summary statistics are represented as mean (standard deviation [SD]) for continuous variables and No. (%) for categorical variables.
Abbreviations: ADT, androgen deprivation therapy; BT, brachytherapy; CDCI, Charlson-Deyo Comorbidity Index; EBRT, external beam radiotherapy; PSA, prostate specific antigen.
Proportion of adults in the patient’s zip code who did not graduate from high school.
A CDCI score of 1 means that an individual has a history of one of the following: myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic pulmonary disease, rheumatologic disease, peptic ulcer disease, mild liver disease, or diabetes.